Previous close | 53.80 |
Open | 79.50 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 21.00 |
Expiry date | 2024-08-16 |
Day's range | 53.80 - 79.50 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.